Iothalamate Meglumine

CHEMBL1201125 Phase 4 Zugelassen Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
809.1 g/mol
LogP
Phase
4

An iodinated contrast agent injected into blood vessels or body cavities to make them visible on X-ray or CT images. It is also used to measure kidney filtration rate (GFR) and to opacify the urinary tract during imaging studies.

Molekularmasse

809,1000 g/mol

TPSA

209,00 Ų

Therapeutische Bereiche

Wirkmechanismus

Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanismus

Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.

2D-Struktur

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CNC(=O)c1c(I)c(NC(C)=O)c(I)c(C(=O)O)c1I.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO

InChI

InChI=1S/C11H9I3N2O4.C7H17NO5/c1-3(17)16-9-7(13)4(10(18)15-2)6(12)5(8(9)14)11(19)20;1-8-2-4(10)6(12)7(13)5(11)3-9/h1-2H3,(H,15,18)(H,16,17)(H,19,20);4-13H,2-3H2,1H3/t;4-,5+,6+,7+/m.0/s1

Molecular Formula

C18H26I3N3O9

HBD / HBA

9 / 10

Rotierbare Bindungen

9

Schwere Atome

33

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

An iodinated contrast agent injected into blood vessels or body cavities to make them visible on X-ray or CT images. It is also used to measure kidney filtration rate (GFR) and to opacify the urinary tract during imaging studies.

Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.

Yes, Iothalamate Meglumine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201125. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 656642. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.